Domov › Nemalobunkový karcinóm pľúc › Florida

Klinické štúdie Nemalobunkový karcinóm pľúc v štáte Florida

155 štúdií pre Nemalobunkový karcinóm pľúc hľadá účastníkov v zariadeniach v štáte Florida.

Mestá v štáte Florida

Oficiálny text štúdie (anglicky)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Mount Sinai Comprehensive Cancer Center at Aventura, Aventura
Holy Cross Hospital, Fort Lauderdale
Regional Cancer Center-Lee Memorial Health System, Fort Myers
a 6 ďalších

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156), Fort Lauderdale
Miami Cancer Institute at Baptist Health, Inc. ( Site 0214), Miami

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06623422

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Cancer Specialists of North Florida - Fleming Island, Fleming Island
Cancer Specialists of North Florida - Riverside, Jacksonville
Cancer Specialists of North Florida Southside, Jacksonville
a 6 ďalších

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06472245

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

University of Miami - Sylvester Comprehensive Cancer Center, Miami
Advent Health, Orlando
Florida Cancer Specialists South, Port Charlotte

Prebieha náborFáza 1/2

Vek 12 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT04585750

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Florida Clinical Trials Group, Plantation
Florida Clinical Trials Group - Tamarac, Tamarac

Prebieha náborFáza 2/3

Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT07365319

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Mayo Clinic in Florida, Jacksonville

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06265285

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #48, Celebration
Exelixis Clinical Site #11, Gainesville
Exelixis Clinical Site #78, Jacksonville
a 2 ďalších

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT05176483

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

AdventHealth Medical Group Oncology Research at Celebration, Kissimmee

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06172478

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Cancer Specialists of North Florida /ID# 277332, Jacksonville
Cancer Care Centers of Brevard- Rockledge /ID# 277853, Rockledge
Moffitt Cancer Center /ID# 276785, Tampa

Prebieha náborFáza 2/3

Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT07155187

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Moffitt Cancer Center, Tampa

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06625775

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Morton Plant Hospital, Clearwater
Miami Cancer Institute, Miami
South Florida Baptist Hospital, Plant City
a 6 ďalších

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06498635

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Research Site, Jacksonville

Prebieha náborFáza 1/2

Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06996782

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

ALX Center 7, Tampa

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07085091

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Local Institution - 0711, Ocala
Local Institution - 0935, Plantation

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07361497

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Clermont Oncology Center, Clermont
Advanced Research, Coral Springs
BRP- Hialeah Hospital, Hialeah
a 1 ďalších

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07361510

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

BRCR Global- Tamarac, Tamarac
Moffit Cancer Centre, Tampa

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07659782

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Sylvester Comprehensive Cancer Center Miami, Miami
AdventHealth Cancer Institute, Orlando
H Lee Moffitt Cancer Center and Research Institute, Tampa

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT06765109

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Research Site, Jacksonville

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT05877599

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Mayo Clinic Hospital Jacksonville /ID# 275073, Jacksonville
Mid Florida Hematology And Oncology Center /ID# 273777, Orange City

Prebieha náborFáza 1/2

Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT06772623

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Florida Cancer Specialists & Research Institute - Sarasota Cattlemen, Sarasota

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT07578571

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Florida Cancer Specialists & Research Institute - South, Fort Myers
BRCR Global, Plantation
Cancer Care Centers of Breevard, Rockledge
a 3 ďalších

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT06881784

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Cancer Care Centers of Brevard, Inc., Palm Bay
Florida Cancer Affiliates - Panama City, Panama City

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07144280

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Mount Sinai Medical Center, Miami Beach
AdventHealth, Orlando

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT05498428

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Mayo Clinic in Florida ( Site 0014), Jacksonville
Mount Sinai Cancer Center ( Site 0038), Miami Beach
Mid Florida Hematology and Oncology Center ( Site 0018), Orange City

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06312137

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Florida Cancer Specialists, Bonita Springs
Florida Cancer Specialists, Bradenton
Florida Cancer Specialists, Cape Coral
a 46 ďalších

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07222566

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Boca Raton Clinical Research Coral Springs, Coral Springs
Florida Clinical Trials Group Plantation, Plantation
Florida Clinical Trials Group Tamarac, Tamarac

Prebieha náborFáza 3

Vek 18 až 100 · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT05920356

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Research Site, Jacksonville

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06218914

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Mayo Clinic Jacksonville, Jacksonville
Moffitt Cancer Center, Tampa

Prebieha náborObservačná štúdia

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT04981119

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Mid Florida Hematology and Oncology Center, Orange City
BRCR Global, Plantation

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06758401

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Baptist Lynn Cancer Institute, Boca Raton
The Oncology Institute of Hope and Innovation 1, Fort Lauderdale
Florida Cancer Specialists, Fort Myers
a 12 ďalších

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06667076

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mayo Clinic Jacksonville, Jacksonville

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07154290

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

University of Miami, Miami
Orlando Health Cancer Institute, Orlando

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06667908

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133), Jacksonville

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06170788

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

BRCR Medical Center Inc., Coral Springs
Mid Florida Hematology and Oncology Center, Orange City
Orlando Health Ambulatory Care Center, Orlando
a 3 ďalších

Prebieha náborFáza 1/2

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07227298

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Research Site, Bay Pines
Research Site, Clearwater
Research Site, Gainesville
a 1 ďalších

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06868277

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Boca Raton Regional Hospital, Boca Raton
Florida Cancer Specialists - South, Fort Myers
Miami Cancer Institute at Baptist Health, Inc., Miami
a 5 ďalších

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06890598

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

MDR Core Network, Boynton Beach

Prebieha náborFáza 1/2

Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06047379

Pan-tumor MRD Study

Oncology & Hematology Associates of West Broward, Coral Springs
Mid Florida Cancer Centers, Orange City
Comprehensive Hematology Oncology (CHO), St. Petersburg

Prebieha náborObservačná štúdia

Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06605404

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Holy Cross Hospital, Fort Lauderdale

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT03191149

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Memorial Hospital West, Pembroke Pines
Florida Cancer Specialists - North, St. Petersburg
Florida Clinical Trials Group., Tamarac
a 1 ďalších

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT06561386

Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.